title: Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma.
abstract: BACKGROUND
  Angiogenesis is essential for tumour growth and metastasis. There are conflicting reports as to whether microvessel density (MVD) using the endothelial marker CD105 (cluster of differentiation molecule 105) in clear-cell renal cell carcinomas (ccRCC) is associated with prognosis. Recently, CD105 has been described as a RCC cancer stem cell marker.
  
  
  METHODS
  A total of 102 ccRCC were analysed. Representative tumour sections were stained for CD105. Vascularity (endothelial CD105) was quantified by MVD. The immunohistochemistry analysis detected positive (if present) or negative (if absent) CD105 tumoral staining. This retrospective population-based study was evaluated using Kaplan-Meier method, t-test and Cox proportional hazard model.
  
  
  RESULTS
  We found that the expression of endothelial CD105 (MVD) negatively correlated with nuclear grade (P<0.001), tumour stage (P<0.001) and Leibovitch score (P<0.001), whereas the expression of tumoral CD105 positively correlated with these three clinicopathological factors (P<0.001). In multivariate analysis, tumoral CD105 was found to be an independent predictor of poor overall survival (P=0.002).
  
  
  CONCLUSIONS
  We have shown for the first time that tumoral CD105 is an independent predictive marker for death risk and unfavourable prognosis in patients with ccRCC after curative resection.
authors.affiliation: 1] INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France [2] Medical Oncology department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
authors.forename: A
authors.initials: A
authors.lastname: Saroufim
authors.affiliation: INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Messai
authors.affiliation: INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
authors.forename: M
authors.initials: M
authors.lastname: Hasmim
authors.affiliation: Department of Pathology, Pontchaillou Hospital, 2 rue Henri Le Guilloux, 35033 Rennes, France.
authors.forename: N
authors.initials: N
authors.lastname: Rioux
authors.affiliation: Medical Oncology department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
authors.forename: R
authors.initials: R
authors.lastname: Iacovelli
authors.affiliation: Department of Pathology, Pontchaillou Hospital, 2 rue Henri Le Guilloux, 35033 Rennes, France.
authors.forename: G
authors.initials: G
authors.lastname: Verhoest
authors.affiliation: Department of Pathology, Pontchaillou Hospital, 2 rue Henri Le Guilloux, 35033 Rennes, France.
authors.forename: K
authors.initials: K
authors.lastname: Bensalah
authors.affiliation: 1] INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France [2] Urologic Department, Kremlin-Bicêtre Hospital, 78 rue de General Leclerc, 94275 Le Kremlin Bicêtre, France.
authors.forename: J-J
authors.initials: JJ
authors.lastname: Patard
authors.affiliation: 1] INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France [2] Medical Oncology department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
authors.forename: L
authors.initials: L
authors.lastname: Albiges
authors.affiliation: Department of Immunology, Istituto Giannina Gaslini, 16100 Genova, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Azzarone
authors.affiliation: 1] INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France [2] Medical Oncology department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
authors.forename: B
authors.initials: B
authors.lastname: Escudier
authors.affiliation: INSERM U753, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
authors.forename: S
authors.initials: S
authors.lastname: Chouaib
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000502:physiology*; D014408:Biomarkers, Tumor / Q000502:physiology*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000401:mortality / Q000601:surgery; D000071063:Endoglin; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000502:physiology*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface